HK1078858A1 - Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders - Google Patents

Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders

Info

Publication number
HK1078858A1
HK1078858A1 HK05110731.8A HK05110731A HK1078858A1 HK 1078858 A1 HK1078858 A1 HK 1078858A1 HK 05110731 A HK05110731 A HK 05110731A HK 1078858 A1 HK1078858 A1 HK 1078858A1
Authority
HK
Hong Kong
Prior art keywords
dihydrobenzodiazepin
derivatives
treatment
neurological disorders
neurological
Prior art date
Application number
HK05110731.8A
Other languages
English (en)
Inventor
Geo Adam
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1078858A1 publication Critical patent/HK1078858A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK05110731.8A 2002-02-06 2005-11-25 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders HK1078858A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06
PCT/EP2003/000859 WO2003066623A1 (en) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
HK1078858A1 true HK1078858A1 (en) 2006-03-24

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05110731.8A HK1078858A1 (en) 2002-02-06 2005-11-25 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders

Country Status (31)

Country Link
US (1) US6949542B2 (no)
EP (1) EP1474416B1 (no)
JP (1) JP4077411B2 (no)
KR (1) KR20040081486A (no)
CN (1) CN100497333C (no)
AR (1) AR038481A1 (no)
AT (1) ATE374196T1 (no)
AU (1) AU2003205695B8 (no)
BR (1) BR0307474A (no)
CA (1) CA2474219C (no)
DE (1) DE60316538T2 (no)
DK (1) DK1474416T3 (no)
ES (1) ES2294264T3 (no)
GT (1) GT200300028A (no)
HK (1) HK1078858A1 (no)
HR (1) HRP20040678A2 (no)
IL (1) IL163102A (no)
MX (1) MXPA04007516A (no)
MY (1) MY176608A (no)
NO (1) NO327697B1 (no)
NZ (1) NZ534122A (no)
PA (1) PA8565901A1 (no)
PE (1) PE20031011A1 (no)
PL (1) PL372425A1 (no)
PT (1) PT1474416E (no)
RU (1) RU2315764C2 (no)
SI (1) SI1474416T1 (no)
TW (1) TWI326599B (no)
UY (1) UY27654A1 (no)
WO (1) WO2003066623A1 (no)
ZA (1) ZA200406032B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1224175T3 (da) * 1999-10-15 2004-07-12 Hoffmann La Roche Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
JP5005343B2 (ja) * 2003-07-25 2012-08-22 エフ.ホフマン−ラ ロシュ アーゲー 急性及び/又は慢性神経障害の治療のためのmGluR2アンタゴニストとAChEインヒビターの併用
CA2623721C (en) 2005-09-27 2014-05-13 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2684760A1 (en) * 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
AU2008291148B2 (en) 2007-08-27 2011-03-17 F. Hoffmann-La Roche Ag Benzimidazole derivatives used as FXR agonists
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
EP2205565B1 (en) 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
AU2009279787B2 (en) 2008-08-04 2014-05-29 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2468733A4 (en) 2009-08-21 2013-02-06 Otsuka Pharma Co Ltd PROCESS FOR PRODUCING BENZO [B] [1,4] DIAZEPINE-2,4-DIONE COMPOUND
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
MX2012008346A (es) 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP6240063B2 (ja) * 2011-04-28 2017-11-29 ザ ブロード インスティテュート, インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2013033246A2 (en) 2011-08-29 2013-03-07 Braincells, Inc. Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9790184B2 (en) 2012-07-27 2017-10-17 The Broad Institute, Inc. Inhibitors of histone deacetylase
AU2013336863A1 (en) 2012-10-23 2015-03-19 F. Hoffmann-La Roche Ag MGlu2/3 antagonists for the treatment of autistic disorders
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ[1,5−d][1,4]オキサゼピン化合物(TETRAHYDROIMIDAZO[1,5−d][1,4]OXAZEPINECOMPOUND)
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052172T3 (es) * 1989-03-23 1994-07-01 Pfizer Agentes antialergicos basados en diazepina.
RU2259360C2 (ru) 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
DK1224175T3 (da) 1999-10-15 2004-07-12 Hoffmann La Roche Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister

Also Published As

Publication number Publication date
AU2003205695B8 (en) 2008-05-01
PL372425A1 (en) 2005-07-25
WO2003066623A1 (en) 2003-08-14
ZA200406032B (en) 2005-10-12
NO20043237L (no) 2004-08-02
PA8565901A1 (es) 2003-09-05
US6949542B2 (en) 2005-09-27
KR20040081486A (ko) 2004-09-21
SI1474416T1 (sl) 2008-02-29
AU2003205695B2 (en) 2008-04-03
GT200300028A (es) 2004-06-11
AR038481A1 (es) 2005-01-19
PE20031011A1 (es) 2003-11-29
ATE374196T1 (de) 2007-10-15
AU2003205695A1 (en) 2003-09-02
UY27654A1 (es) 2003-08-29
EP1474416B1 (en) 2007-09-26
EP1474416A1 (en) 2004-11-10
DE60316538T2 (de) 2008-08-21
CA2474219C (en) 2010-04-13
CN100497333C (zh) 2009-06-10
CA2474219A1 (en) 2003-08-14
DK1474416T3 (da) 2008-01-14
RU2004126945A (ru) 2005-06-27
NO327697B1 (no) 2009-09-14
IL163102A (en) 2011-07-31
ES2294264T3 (es) 2008-04-01
HRP20040678A2 (en) 2005-10-31
MY176608A (en) 2020-08-18
BR0307474A (pt) 2004-11-09
MXPA04007516A (es) 2004-11-10
PT1474416E (pt) 2007-12-27
TW200302730A (en) 2003-08-16
US20030166639A1 (en) 2003-09-04
NZ534122A (en) 2006-12-22
RU2315764C2 (ru) 2008-01-27
JP2005522440A (ja) 2005-07-28
CN1633430A (zh) 2005-06-29
JP4077411B2 (ja) 2008-04-16
TWI326599B (en) 2010-07-01
DE60316538D1 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
HK1078858A1 (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
IL169091A0 (en) Benzazepine derivatives for the treatment of neurological disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
ZA200401004B (en) Combination for the treatment of inflammatory disorders
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
AP2005003274A0 (en) Thiazole compounds for the treatment of neurodegenerative disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
HK1080859A1 (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
HK1099244A1 (en) Tetrahydroindolone derivatives for treatment of neurological conditions
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
IL172377A0 (en) 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0216097D0 (en) Treatment of proliferative disorders
SI1534391T1 (sl) Novi piperazinil-pirazinonski derivati za zdravljenje motenj, povezanih z receptorjem 5-HT2A
GB0326967D0 (en) Use of pyrimidine derivatives for the treatment of psychiatric disorders
AU2002322397A1 (en) Combination therapy for the treatment of neurological disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130128